EUVIMEDEUVIMED entdecken
Open Access

Broussoflavonol F Alleviates Obesity‐Associated Metabolic Syndrome in Obese Mice by Modulating Gut Microbiota

Cunzhen Zhao, Qingya Huang, Shaocong Zhang, Yuxin Han, Yingying Tu, Zhongke Zhu

Molecular Nutrition & Food Research · 2026

DOI: 10.1002/mnfr.70564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2026. Verfasst von Cunzhen Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Xinyang Normal University, Xinyang, People's Republic of China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Obesity, Metabolic Syndrome, Flavonols. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Henan International Science and Technology Cooperation Cultivation Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a global health challenge associated with gut microbiota dysbiosis, which contributes to metabolic dysfunction and fat accumulation. This study explored the anti‐obesity effects of Broussonetia flavonol F (BPF) and its ability to modulate gut microbiota in high‐fat diet (HFD)‐induced obese mice. After 6 weeks of BPF treatment, obese mice exhibited significant reductions in body weight, adipose tissue mass, and serum lipid levels (TC, TG, and LDL‐C), alongside improved glucose tolerance. BPF inhibited fat deposition by downregulating key adipogenic and lipogenic genes in both inguinal adipose tissue (i‐WAT) and epididymal adipose tissue (e‐WAT). Additionally, BPF improved gut barrier function and reduced TNF‐α and IL‐6 levels. 16S rRNA sequencing revealed that BPF restored gut microbiota diversity, increasing the abundance of beneficial bacteria such as Lactobacillus, while decreasing the Firmicutes/Bacteroidetes ratio, a marker of obesity‐related dysbiosis. Mechanistically, the anti‐obesity effects of BPF were abolished in antibiotic‐treated mice and were reproduced by FMT from BPF‐treated donors, confirming a gut microbiota‐dependent mechanism. Our findings demonstrate that BPF alleviates obesity by reshaping gut microbiota structure and suppressing metabolic inflammation, highlighting its potential as a therapeutic agent for obesity management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeObesityMetabolic SyndromeFlavonolsAnimalsMaleDiet, High-FatMice, Inbred C57BLDysbiosisMice, ObeseMiceAnti-Obesity Agents

Stichwörter der Autor:innen

Broussonetia flavonol FFMTgut microbiotametabolic inflammationobesity

Substanzen

Anti-Obesity AgentsFlavonols

Autor:innen und Institutionen

  • College of Life Science, Xinyang Normal University, Xinyang, People's Republic of China.
  • College of Animal Science and Technology, Xinyang Agriculture and Forestry University, Xinyang, People's Republic of China.

Förderung

  • Henan International Science and Technology Cooperation Cultivation Project
  • National Natural Science Foundation of China

Zitieren

APA

Zhao, C., Huang, Q., Zhang, S., Han, Y., Tu, Y., & Zhu, Z. (2026). Broussoflavonol F Alleviates Obesity‐Associated Metabolic Syndrome in Obese Mice by Modulating Gut Microbiota. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70564

Vancouver

Zhao C, Huang Q, Zhang S, Han Y, Tu Y, Zhu Z. Broussoflavonol F Alleviates Obesity‐Associated Metabolic Syndrome in Obese Mice by Modulating Gut Microbiota. Molecular Nutrition & Food Research. 2026. doi:10.1002/mnfr.70564

BibTeX
@article{Zhao2026,
  author = {Zhao, Cunzhen and Huang, Qingya and Zhang, Shaocong and Han, Yuxin and Tu, Yingying and Zhu, Zhongke},
  title = {Broussoflavonol F Alleviates Obesity‐Associated Metabolic Syndrome in Obese Mice by Modulating Gut Microbiota},
  journal = {Molecular Nutrition & Food Research},
  year = {2026},
  doi = {10.1002/mnfr.70564}
}
Kostenlos starten →